Resources Repository
-
GuidelinesPublication 2012Modeling Good Research Practices - Overview: A Report of the ISPOR-SMDM Modeling Task Force-1
This paper provides an overview of the work of the joint Task Force between the …
This paper provides an overview of the work of the joint Task Force between the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the Society for Medical Decision Making (SMDM), provides the overarching recommendations, and discusses future work that is needed. The audience for these papers includes anyone who build models, stakeholders who utilize their results, and those concerned with the use of models to support decision making. This article is part 1 of…
Costing Methods | Health Outcomes | Value of Information | Mathematical Models | State-Transition | Dynamic Transmission | Microsimulation | Calibration/Validation | Dynamic Simulation | Decision Analysis | Infectious Diseases | Health/Medicine -
GuidelinesPublication 2016Decision Models in Clinical Preventive Services Recommendations
The U.S. Preventive Services Task Force (USPSTF) develops evidence-based recommendations about preventive care based on …
The U.S. Preventive Services Task Force (USPSTF) develops evidence-based recommendations about preventive care based on comprehensive systematic reviews of the best available evidence. Decision models provide a complementary, quantitative approach to support the USPSTF as it deliberates about the evidence and develops recommendations for clinical and policy use. This article describes the rationale for using modeling, an approach to selecting topics for modeling, and how modeling may inform recommendations about clinical preventive services.
Health Outcomes | Evidence Synthesis | Mathematical Models | Decision Analysis | Health Systems | Policy/Regulation | Health/Medicine | North America -
GuidelinesPublication 2016Second Panel on Cost-Effectiveness in Health and Medicine
This article provides an overview of the main recommendations of the 2016 Second Panel on …
This article provides an overview of the main recommendations of the 2016 Second Panel on Cost-Effectiveness in Health and Medicine. In 1993, the U.S. Public Health Service convened the first panel of experts to review the state of cost-effectiveness analysis and to develop guidelines for its use in health, to improve quality and promote comparability. Scientists and scholars in economics, clinical medicine, ethics, and statistics met to share expertise and develop recommendations by consensus. The…
Priority Setting/Ethics | Costing Methods | Evidence Synthesis | Cost-Effectiveness Analysis | Technology Assessment | Health/Medicine | North America -
GuidelinesPublication 2014Methods for Economic Evaluation Project
This report details the work of the Methods for Economic Evaluation Project (MEEP), which aims …
This report details the work of the Methods for Economic Evaluation Project (MEEP), which aims to promote a consistency in the methods used for economic evaluations. The report is targeted especially at low and middle-income countries (LMICs). The Bill and Melinda Gates Foundation is a major funder of health economic evaluations in LMICs, but there is substantial variation in the methods used and the quality of the analyses produced. The report drew on expertise from…
Benefit-Cost Analysis | Priority Setting/Ethics | Costing Methods | Cost-Effectiveness Analysis | Climate/Environment | Education/Labor | Health/Medicine | Global -
GuidelinesPublication 2013Economic Analyses to Support Decisions about HPV Vaccination in Low- and Middle-Income Countries: Consensus Report and Guide
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability …
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability before introducing a program for human papillomavirus (HPV) vaccination. However, many such countries lack the technical capacity and data to conduct their own analyses. This report describes the consensus of an expert group convened by the World Health Organization, prioritizing key issues to be addressed when considering economic analyses to support HPV vaccine introduction in these countries. The expert group…
Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Health Systems | Economics/Finance | Health/Medicine | Science/Technology | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
GuidelinesPublication 2012Model Transparency and Validation: A Report of the ISPOR-SMDM Modeling Task Force-7
This paper discusses how to improve trust in the use of health care models through …
This paper discusses how to improve trust in the use of health care models through validation and transparency. Validation involves face validity (wherein experts evaluate model structure, data sources, assumptions, and results), verification or internal validity (check accuracy of coding), cross validity (comparison of results with other models analyzing same problem), external validity (comparing model results to real-world results), and predictive validity (comparing model results with prospectively observed events). Recommendations are provided for nontechnical description…
Costing Methods | Health Outcomes | Mathematical Models | Calibration/Validation | Health/Medicine -
GuidelinesPublication 2018Latent TB Infection: Updated & Consolidated Guidelines for Programmatic Management
Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation …
Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens with no evidence of clinically manifest active TB. Up to one third of the world’s population is estimated to be infected with Mycobacterium tuberculosis, and on average, 5–10% of those who are infected will develop active TB disease over their lifetime. The management of LTBI involves a comprehensive package of interventions: identifying and testing those individuals…
Evidence Synthesis | Infectious Diseases | Health/Medicine | Global -
GuidelinesPublication 2017Guidelines for Regulatory Impact Analysis: A Primer
This “Frequently Asked Question” style document gives a brief overview of Regulatory Impact Analysis (RIA), …
This “Frequently Asked Question” style document gives a brief overview of Regulatory Impact Analysis (RIA), a method used by the US government to assess the consequences of proposed policies and their alternatives. The document is aimed at those who are new to the topic. RIAs apply a framework for collecting, organizing, and evaluating data. They help ensure that regulatory actions are justified and necessary to achieve social goals, and that these actions are implemented in the…
Benefit-Cost Analysis | Business/Industry | Government/Law | North America -
GuidelinesPublication 2016Estimating Health-State Utility for Economic Models: ISPOR Task Force Report
Cost-utility models are increasingly used in many countries to establish whether the cost of a …
Cost-utility models are increasingly used in many countries to establish whether the cost of a new intervention can be justified in terms of health benefits. Health-state utility (HSU) estimates (the preference for a given state of health on a cardinal scale where 0 represents dead and 1 represents full health) are typically among the most important and uncertain data inputs in cost-utility models. Clinical trials represent an important opportunity for the collection of health-utility data.…
Preferences/Values | Health Outcomes | Mathematical Models | Cost-Effectiveness Analysis | Technology Assessment | Health Systems | Health/Medicine | Science/Technology | North America | Europe